Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34475471 | 0.93 | ALDH1A1 (0.49) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2669559 | 0.89 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2432866 | 0.87 | MAPT (0.47) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2432863 | 0.87 | MAPT (0.47) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2432868 | 0.87 | MAPT (0.47) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20827317 | 0.86 | ALDH1A1 (0.69) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18204624 | 0.84 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15105909 | 0.84 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18204623 | 0.84 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL31585895 | 0.84 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005014519-A1 | PROCESS FOR THE PREPARATION OF GEMINAL DIFLUOROALKANES | HONEYWELL SPECIALTY CHEMICALS SEELZE GMBH (DE) | 2005-02-17 | — | — | WO | claimed |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2025-08-07 | — | — | US | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250223259-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | MERCK SHARP & DOHME LLC (US) | 2025-07-10 | — | — | US | disclosed |
| EP-4568959-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-0888337-B1 | PIPERIDONE TACHYKININ ANTAGONISTS | PFIZER RES & DEV (IE) | 2002-06-05 | — | — | EP | disclosed |
| CN-1072666-C | (Azetidin-1-ylalkyl) lactams as tachykinin antagonists | PFIZER RES AND DEV CO N V S A (IE) | 2001-10-10 | — | — | CN | disclosed |
| US-6262075-B1 | Piperidone tachykinin antagonists | PFIZER INC | 2001-07-17 | — | — | US | disclosed |
| EP-0775132-B1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LTD (GB) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| US-5968923-A | ANTIINFLAMMATORY AGENTS, TREATMENT OF NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS | PFIZER INC. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0888337-A1 | PIPERIDONE TACHYKININ ANTAGONISTS | Pfizer Research and Development Company, N.V./S.A. (IE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997027185-A1 | PIPERIDONE TACHYKININ ANTAGONISTS | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-07-31 | — | — | WO | disclosed |
| CN-1154699-A | (Azetidin-1-ylalkyl) lactams as tachykinin antagonists | PFIZER LTD (IE) | 1997-07-16 | — | — | CN | disclosed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | SAMHD1, IRF3, SLC34A1 | MAPT 1379/4885ALDH1A1 3488/4885CYP3A4 939/4885 |
| US-20250223259-A1 | PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION | ACE2, PRSS2, PRSS1 | MAPT 3125/4885ALDH1A1 3512/4885CYP3A4 323/4885 |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ZC3HAV1, GTF3C1, ODC1 | MAPT 4622/4885ALDH1A1 759/4885CYP3A4 281/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | MAPT 611/4885ALDH1A1 3433/4885CYP3A4 2024/4885 |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, REV1, RTF2 | MAPT 1650/4885ALDH1A1 3189/4885CYP3A4 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.